Abstract:When not treated properly, Rheumatoid arthritis (RA) progresses in its chronic course, joint damage increases, and it can even lead to systemic involvement. Methotrexate (MTX), is the most preferred drug in RA treatment. However, there is no agreement among physicians on the dose of methotrexate. The aim of this study was to determine the effects and side effects of high dose methotrexate use in the initial combined therapy on the activity of disease among active RA patients. Newly diagnosed 45 RA patients were divided into two groups randomly. First group received 12,5 mg/week MTX im for four weeks and continued orally. Second group received 25 mg/week MTX im for four weeks and continued with 12,5 mg/week orally. Beside the MTX treatment, 2 gr/day SLZ and 5 mg/day prednisolone were given to both groups. At three different stages of the treatment patients were evaluated in terms of DAS28, MHAQ, VAS, morning stiffness, ESR and CRP. Patients were 34 female and 11 male. Mean disease duration was 14.7 months. In 1st group, mean DAS28 was 6.51 at the beginning, and in the end of the 3rd month it decreased to 2.75. In second group, mean DAS28 was 6.05 at the beginning, and in the end of the 3rd month it decreased to 3.56. Tender joint count in second group was 3.17 at the 3rd month, whereas it was 1.64 at the first group. In the 3rd month, at the high dose MTX group, VAS, DAS28 showed statistically significant improvement when compared to parameters of other group. CRP, morning stiffness, swollen joint count, and MHAQ scores at the 25mg/week MTX group were better at the 1st and 3rd months; however, there was no statistically significant difference between two groups in terms of those parameters. Three patients had nausea, fatigue, vomiting. At the 3rd month, at first group treatment was changed in one patient only. At second group, treatment was changed in 4 patients. In one patient, nausea and vomiting developed and ALT increased in another patient. Although scores of 1st month didn't show a significant difference between two groups, scores of 3rd month in the high dose MTX group exhibited a marked improvement in all criteria except morning stiffness. Improvements in DAS28 and number of sensitive joints were statistically significant. ACR 20,50,70 and 90 improvements of 3rd month in the high dose MTX group were higher than those of first group. In 2010, a new classification criteria for RA was developed, which makes early diagnosis of RA possible. The treatment includes the use of MTX plus combined DMARDs at the early stages of active disease. Findings of this study demonstrated that usage of high dose MTX at an early stage is more effective in controlling the disease activity and increases the quality of life in RA. Patients receiving high dose metotrexate, needed less treatment change at the end of the 3rd month. Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford). 2004 May;43(5):678-9. Miyasaka N.Paradigm shift and future perspectives in rheumatoid arthritis.Nihon Rinsho. 2013 Jul;71(7):1141-6. Review. Japanese None declared 10.1136/annrheumdis-2014-eular.3135

The impact of low-dose methotrexate on erectile dysfunction, sex hormone profile and spermiogram in male patients with psoriasis: a prospective study

Can methotrexate influence sexual dysfunction in male patients? Analysis of the IIEF5 questionnaire and hormonal status

Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients

Sex-differential Downregulation of Methotrexate on Plasma Viscosity and Whole Blood Viscosity in Psoriasis

Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study

The Effect of Methotrexate on Serum Levels of Trace/Mineral Elements in Patients with Psoriatic Arthritis

The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting

Impact of adalimumab on erectile dysfunction, sperm parameters and hormonal profile in male psoriasis patients: a six-month observational study

Evaluation the Effect of Methotrexate on Psoriasis Based on Specialized Pharmaceutical Education

Safety and Efficacy of Methotrexate for Chinese Adults with Psoriasis with and Without Psoriatic Arthritis

Etanercept versus Methotrexate in the Treatment of Psoriasis and Associated Metabolic Syndrome: 12 Months Open-Label Comparative Study

The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B/apolipoprotein A-1 ratio

Efficacy and safety of isotretinoin in comparison to methotrexate in the patients suffering from moderate-to-severe plaque psoriasis: A prospective cohort study

AB0470 A Research Evaluating the Effectiveness and the Side Effects of High Dose Methotrexate Use in Combined Therapy of Rheumatoid Arthritis

Methotrexate: new therapeutic approaches

Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

The investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgaris

Association of the characteristics of the blood metabolome and gut microbiome with the outcome of methotrexate therapy in psoriasis

The Impacts of Gene Polymorphisms on Methotrexate in Chinese Psoriatic Patients

S1724 Risk of Hepatotoxicity With Long-Term Methotrexate Use: A Systematic Review and Meta-Analysis

A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate